Table 1.
Patient characteristics.
| Study Cohort (n = 63) | No SOS/VOD (n = 60) | SOS/VOD (n = 3) | ||
|---|---|---|---|---|
| disease type | AML | 28 (44.4%) | 27 | 1 |
| MDS | 13 (20.6%) | 13 | 0 | |
| lymphoma | 7 (11.1%) | 7 | 0 | |
| ALL | 8 (12.7%) | 6 | 0 | |
| CML | 3 (4.8%) | 2 | 1 | |
| lymphomatoid granulomatosis | 1 (1.6%) | 1 | 0 | |
| hypereosinophilic syndrome | 1 (1.6%) | 1 | 0 | |
| MM | 1 (1.6%) | 0 | 1 | |
| ET | 1 (1.6%) | 1 | 0 | |
| stem cell donor | matched unrelated | 47 (74.6%) | 45 | 2 |
| matched related | 8 (12.7%) | 8 | 0 | |
| mismatch | 8 (12.7%) | 6 | 1 | |
| conditioning regimen | MAC | 20 (31.7%) | 17 | 3 |
| RIC | 43 (68.3%) | 43 | 0 | |
| gender | female | 20 (31.7%) | 19 | 1 |
| male | 43 (68.3%) | 41 | 2 | |
| age (years) | 55 | 54.9 | 48.3 | |
| baseline SWE (m/S) | 1.42 | 1.43 | 1.29 | |
| baseline SWE (kPa) | 6.1 | 6.2 | 4.9 | |
| baseline PV velocity (cm/S) | 22.5 (n = 57) | 22.4 | 24.7 | |
Abbreviations: AML acute myeloid leukemia; MDS myelodysplastic syndrome; ALL acute lymphoblastic leukemia; CML chronic myeloid leukemia; MM multiple myeloma; ET essential thrombocytosis; SWE shear wave elastography; PV portal vein; MAC myeloablative conditioning with busulfan 4 × 3.2 mg/kg and 2× cyclophosphamide 60 mg/kg for AML, CML and MDS, 12 Gy and 2 × 60 mg/kg cyclophosphamide i.v. or 8 Gy and 4 × 30 mg/m2 fludarabine for ALL, TTF (3 × 12 g/m2 treosulfan, 5 × 30 mg/m2 fludarabine and 2.5 mg/kg thiotepa) for multiple myeloma; RIC = reduced conditioning with 3 × 12 g/m2 treosulfan and 5 × 30 mg/m2 fludarabine or 5 × 30 mg/m2 fludarabine and 2 × 3.2 mg/kg busulfan i.v.